ReviewHeliyon2023
The use of clinical scales and PROMs in headache disorders and migraine, summarizing their dissemination and operationalization.
Review in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Ultrasound-guided greater occipital nerve block for chronic migraine: a systematic review and meta-analysis.Head & face medicine · 2025Pooled it
- The impact of primary headaches on disability outcomes: a literature review and meta-analysis to inform future iterations of the Global Burden of Disease study.The journal of headache and pain · 2024Pooled it
- Targeting individual pain catastrophizing to reduce migraine-related disability: a randomized controlled proof-of-concept trial using an online CBT intervention.Scientific reports · 2026Trial
- Psychological transdiagnostic factors and migraine characteristics as predictors of migraine-related disability.The journal of headache and pain · 2025Trial
- Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry.The journal of headache and pain · 2026Article
- MIDAS and HIT-6 Questionnaires Versus Headache Diaries for Monitoring Treatment Response to Erenumab in Migraine: A REFORM Study.European journal of neurology · 2026Article
- Article
- Development and validation of a patient-reported-experience measure to ascertain treatment satisfaction in migraine: the MISAT-Q questionnaire.Journal of patient-reported outcomes · 2025Article
- Turkish version, validity, and reliability of the Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire (JHEQ).BMC musculoskeletal disorders · 2025Article
- Changes in P2X4 receptor expression following AbobotulinumtoxinA treatment in patients with chronic migraine: A case series study.Current journal of neurology · 2025Article
- Patients' Global Impression of Change (PGIC) Score Compared to Monthly Migraine Days to Evaluate Treatment Persistence With Anti-CGRP Monoclonal Antibodies.Annals of clinical and translational neurology · 2025Article
- Validation of the Spanish Version of the Headache Impact Test (HIT-6) in Patients With Episodic Migraine.Brain and behavior · 2025Article
- Headache Disability Questionnaire: cross-cultural adaptation and validation of the Turkish version.BMC neurology · 2024Observational
- The abnormally increased functional connectivity of the locus coeruleus in migraine without aura patients.BMC research notes · 2024Article
- Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study.The journal of headache and pain · 2024Observational
- Frequency and predictors of headache in the first 12 months after traumatic brain injury: results from CENTER-TBI.The journal of headache and pain · 2024Observational
- The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine.Headache · 2024Article
- Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine.Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Measurements are an essential aspect of scientific research. This review will present clinical scales and patient-reported outcome measures (PROMs) for headache disorders and migraine that have been endorsed by the International Headache Society (IHS) and are intended for use by both physicians and researchers. A clinical scale is a tool to assess a patient's condition or symptoms in a standardized and quantifiable way. Clinical scales are often used in research settings and can be used to track a patient's progress over time, monitor the effectiveness of treatment, and make decisions. They can be self-administered or completed by a healthcare professional. PROMs are tools used to evaluate a patient's health status, symptoms, and quality of life. These measures are completed by the patient and provide valuable information about the patient's perspective and experience of their condition. PROMs are increasingly used in clinical practice and research to improve patient-centered care, patient engagement, and shared decision-making. This review also briefly covers the creation process, testing for reliability and validity, and interpreting the results of the use of clinical scales and PROMs in clinical and research settings in headache disorders. The first step in creating a clinical scale or PROM is to define the purpose of the scale and the population it is intended to assess. The next step is to identify the domains or areas that the scale will assess. Then, the items or questions that will be included in the scale need to be developed. These items should be relevant to the defined purpose and population of the scale and should be worded clearly and concisely. After the items have been developed, the scale or PROM can be administered to a sample of individuals in the target population. This allows researchers to assess the reliability and validity of the scale or PROM, as well as to make any necessary revisions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.